AJAY RAI, M.B.A.
Vice President, Business Development
Ajay is the Vice President, Business Development of Frequency Therapeutics. He brings over 20 years in finance, strategy and business development/M&A experience in the Life Sciences arena. Prior to joining Frequency, Ajay was the Senior Director of Corporate Development for Takeda. In this role, Ajay was responsible for evaluating and leading M&A, divestments, joint ventures and new company formation for all of Takeda’s business. Prior to Takeda, Ajay spent over 10 years at Biogen in a variety of roles, including Business Planning, Investor Relations, Corporate Strategy, Venture Investment and Business Development/M&A. Ajay was responsible for leading BD activities for immunology, pain and tissue injury and fibrosis therapeutic areas, where he completed over fifteen transactions ranging from acquisitions to early stage research partnerships. In addition, Ajay was instrumental in leading new and follow-on investments in multiple early-stage companies for Biogen’s Venture Portfolio. Prior to Biogen he was an M&A advisor for Ernst & Young’s M&A advisory practice. Ajay started his professional career in the Finance and Strategy group of Roche Molecular Systems, the division that developed and commercialized the PCR technology.
Ajay earned a B.S. in finance from New York University’s Stern School of Business, and an M.B.A. from Case Western University.